Who we are
Medicines for Europe
Purpose and Objectives
OUR VALUES
STRUCTURE
OUR MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
JOB OPPORTUNITIES
Key topics
COVID-19
Access
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
Factsheets
Infographics
Reports
Policy
Videos
Podcast
Newsroom
Press releases
In the news
Press kit
Contact us
Login
Generic medicines
Home
Who we are
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Who we are
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Environment of value added medicines in Europe
Definition
THERAPEUTIC AREAS
Q&A
What’s new
Environment of value added medicines in Europe
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Value Added Medicines award 2019
QUOTES
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
VAM Advantages
1 April 2021
Open
Related Posts
Open letter: Urgent call to amend the Temporary State Aid…
17 November 2021
Medicines for Europe, representing manufacturers of generic, biosimilar and value…
Open borders that prioritise essential goods key to…
2 June 2021
Open
Open Public Consultation on the revision of EU rules on…
26 July 2021
Open
Open letter to the Members of the European Parliament on the…
11 September 2019
OPEN
Tweet
Tweet
Tweet
LinkedIn
